The phase 3 SPOTLIGHT study (National Clinical Trials 04186845) evaluated the diagnostic accuracy of 18F-flotufolastat in men who developed BCR after prior curative-intent treatment of prostate cancer.10 Here, BCR is linked to prostate carcinoma.